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Anal cancer is rare, comprising ~2.7% of all malignancies of the 
digestive system.[1] The Surveillance, Epidemiology, and End Results 
(SEER) Program of population-based tumour registries in the USA 
estimated that there were 8 580 new cases in 2018.[2] The incidence of 
anal cancer has increased over the past three decades, both in the USA 
and elsewhere.[3,4] The clinicopathological features of patients with anal 
squamous cell carcinoma and HIV infection remain largely unknown.
Squamous cell carcinoma is the most common anal cancer, followed 
by adenocarcinoma, and the least common varieties are melanoma, 
lymphoma and neuroendocrine tumours.[5] Anal cancer can occur in 
the anal canal or the anal margin, whereas adenocarcinoma occurs 
solely in the anal canal.
Risk factors associated with an increased incidence of anal squa-
mous cell carcinoma include female gender, human papillomavirus 
(HPV) infection, especially subtypes 16 and 18, immunosuppression, 
anoreceptive intercourse, a high lifetime number of sexual partners, 
sexually transmitted diseases, genital warts, smoking and HIV 
infection.[3,4,6,7]
Immunosuppression has in turn been shown to accelerate the 
progression of HPV-associated anal precursor lesions such as anal 
intra epithelial neoplasia (AIN).[8] The incidence of anal cancer is 
markedly elevated among people with HIV infection, especially 
in men who have sex with men (MSM),[9-11] and >40% of patients 
with HIV infection develop a cancer of some sort during their life-
time. [12] However, although anal cancer is one of the HIV-associated 
malignancies (HIVAM), it has not been identified as AIDS defining.[13]
Studies on carcinogenesis have highlighted the role of immuno-
suppression in the accelerated progression of HPV-associated anal 
precursor lesions.[4] Whereas the introduction of antiretroviral therapy 
(ART) has led to improvement of the immune system of infected 
individuals and substantially increases their life expectancy,[14] it 
has not been shown to reduce the prevalence of HPV infection, 
which is the causative agent in >90% of invasive anal carcinomas. [15] 
It therefore appears that the extended survival of HIV-positive 
individuals on ART coupled with the inability of ART to restore 
adequate host immune system function to combat HPV infection and 
progression to malignancy may explain why co-infection with HIV 
and HPV increases HIVAM.[13,14]
There are limited international studies addressing HIV and anal 
cancer. Despite sub-Saharan Africa being an epicentre of HIV 
infection, there are no data on HIV infection and anal cancer from 
Africa. Furthermore, there is little South African (SA) literature 
reporting on anal cancer, and none addressing outcomes in HIV-
positive and HIV-negative patients. International studies can be 
criticised on the grounds of the small numbers of HIV-infected 
patients with anal cancer reported and the fact that their data cannot 
be generalised to the African context, including SA, hence the need to 
address this question from a developing country like SA.
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Background. Anal carcinoma is rare. Clinicopathological features influencing outcome have not been determined in HIV-negative and 
HIV-positive patients in South Africa.
Objectives. To compare presentation and treatment tolerance among HIV-positive and negative patients.
Methods. This study was a retrospective analysis of prospectively collected data on patients with squamous cell carcinoma of the anus. 
Patients with known HIV status were extracted from the anal cancer database and analysed. Data analysed included demographics, clinical 
features, stage, pathology and treatment outcome.
Results. There were 268 patients with anal squamous cell carcinoma (n=135 HIV-positive and n=33 negative). The median age was 39 years 
and 53 years for HIV-positive and negative patients, respectively, the male/female ratio was 1:2.7 and 1:1.8 for the two groups, and the ratio 
of anal margin to canal distribution was 1.3:1 and 1:1. Disease stage was similar, with minor differences. The resection rate was 17% in 
HIV-positive patients and 9% in those who were HIV-negative. Half the patients in both groups were eligible for definitive therapy, and 
side-effects of oncotherapy occurred with similar frequency in both groups. The recurrence rate was 7% in both groups and the disease-free 
interval was similar. Overall survival was longer for HIV-negative patients (p=0.0240).
Conclusions. The prevalence of anal squamous cell carcinoma is much higher in individuals with HIV infection than in those who are HIV-
negative. HIV-positive patients present at a younger age and with locally advanced disease that responds less well to standard treatment, 
and their survival is poorer.
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Objectives
We hypothesised that the clinical presentation of anal cancer in 
HIV-positive patients differs from that in HIV-negative patients. 
In an attempt to address the dearth of knowledge in this area, we 
undertook a retrospective cohort study of patients with squamous cell 
carcinoma of the anus to determine the clinicopathological factors 
that influence outcome in HIV-infected and non-infected patients. 
The study analysed an ongoing anal cancer database in KwaZulu-
Natal Province, SA. Our objective was to determine the demographic 
profile of patients with anal cancer, with special attention to HIV 
infection. This is the first study with a large study population to 
address the clinicopathological spectrum of anal cancer in SA.
Methods
Study setting
The study was undertaken in the colorectal unit at Inkosi Albert 
Luthuli Central Hospital (IALCH), a tertiary referral hospital in 
Durban, SA.
Study population
The study population was previously untreated patients newly 
diagnosed with invasive anal squamous cell carcinoma and managed 
at IALCH. All patients with invasive squamous cell carcinoma were 
included in the study, and those with anal malignancy other than 
squamous cell carcinoma were excluded. Patients whose HIV status 
was known were divided into HIV-negative and positive groups and 
analysed separately. Patients with unknown HIV status were excluded 
from the subsequent subanalysis.
Study design
This was a retrospective cohort study of data collected from the 
ongoing anal cancer database archived in the Gastrointestinal Cancer 
Research Centre of the University of KwaZulu-Natal. Patients with 
anal squamous cell carcinoma were extracted from the database, 
which spanned a period of 18 years from 2000 to 2017. The 
dataset analysed included demographic data such as age, gender, 
tumour stage, HIV status, CD4+ count, treatment received and 
treatment outcome. The TNM Classification of Malignant Tumours 
(8th  edition) and Union for International Cancer Control (UICC) 
staging were used during data capture. For the purposes of this 
article, the UICC staging was used. The following protocol is followed 
in our unit for the management of patients with anal squamous 
cell carcinoma. Patients who present with lesions suspicious of 
anal cancer are initially evaluated in the regional hospitals across 
the province. Once the diagnosis is confirmed and appropriate 
staging investigations have been undertaken, they are then referred 
to the Oncology Unit at IALCH, where they are evaluated in a 
multidisciplinary clinic. Further management is then discussed at a 
multidisciplinary board meeting where a treatment plan is decided 
on based on clinical features, staging and patient performance status.
Therapeutic modalities
Patients with stage I disease were treated with primary resection, 
which involved either wide local excision or abdominoperineal 
resection. Patients requiring definitive therapy received chemo-
radiation. The chemotherapy arm used either a single-agent regimen 
such as capecitabine, cisplatin or carboplatin or combination 
chemotherapy comprising cisplatin plus mitomycin, cisplatin plus 
5-fluorouracil, or mitomycin plus capecitabine. The radiation 
technique varied from three-dimensional conformal radiation to 
volumetric arc therapy with a combination of photons and electron 
boost to the primary and inguinal nodes. The average radiation 
dose was 45 Gy to the primary tumour and pelvic nodes and a 
14.4 Gy electron boost to the primary and inguinal nodes where 
deemed necessary. All patients were initially reviewed 6 weeks after 
completion of treatment and again 6 weeks later. The response to 
treatment was assessed clinically. If the size of the primary tumour 
had decreased by 50%, the clinical response was assessed as partial; 
complete disappearance of disease was considered complete clinical 
response. Persistent non-progressive anal lesions were biopsied to 
confirm the presence of malignancy or to demonstrate complete 
pathological response. Palliative radiation was delivered to the 
primary lesion at various doses in patients with advanced disease 
such as stage IV disease or those with poor performance status.
Data management and statistical analysis
Data were stored on an Excel spreadsheet, version 2016 (Microsoft, 
USA) and analysed using the Statistical Package for the Social Sciences 
(SPSS) (IBM, USA). Dates of death were identified where possible via 
the Department of Home Affairs. Quantitative data were expressed as 
medians and interquartile ranges (IQRs) and comparison was made 
using non-parametric tests. Actuarial survival was analysed using the 
Kaplan-Meier method. The level of significance was set at p<0.05.
Ethical considerations
Ethical approval was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (ref. no. R057/04).
Results
Fig. 1 illustrates the inclusion and exclusion criteria that led to a total 
of 268 patients with squamous cell carcinoma being eligible for initial 
analysis. One hundred and sixty-eight patients agreed to volun tary 
counselling and testing for HIV infection, of whom 135 were HIV-
positive and 33 were HIV-negative (Table 1). One hundred patients 
(n=35 males) were not tested for HIV, either because they refused 
or were not asked to undergo the test. HIV-positive patients were a 
decade younger than their HIV-negative counterparts (p<0.0001). 
Female patients predominated in the cohort as a whole, and the 
proportion of female patients was relatively higher among HIV-
positive patients compared with HIV-negative patients. Anal margin 
disease predominated in the whole group, and this predominance 
was more pronounced among HIV-positive patients than among 
HIV-negative patients. The median duration of symptoms for both 
the HIV-positive and negative groups was 12 (IQR 2 - 24) months. 
Fig. 2 demonstrates the annual accrual of patients with squamous 
cell carcinoma. There was a trend towards increasing diagnosis of 
this cancer over the years.
Staging is shown in Fig. 3. The majority of patients had stage III 
disease, with a higher proportion of HIV-positive patients than HIV-
negative patients. There was a slight increase in the proportion of 
HIV-negative patients in stages II and IV. The trends in staging did 
not reach statistical significance.
Primary management is shown in Table 2. The proportion of 
patients receiving definitive therapy was similar in the two cohorts. 
A higher proportion of HIV-negative than HIV-positive patients 
received palliative therapy (36% v. 24%), and this difference in 
treatment objectives between the two groups did not reach statistical 
significance (p=0.181). The proportion of patients who did not 
receive any treatment at all was higher among HIV-positive patients 
than among those who were HIV-negative (24% v. 12%). Reasons 
for patients receiving no treatment included failure to return, prior 
resection and poor performance status. Complete clinical response 
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was seen in 10/99 HIV-positive patients 
(10%) compared with 5/30 HIV-negative 
patients (17%), and complete pathological 
response in 6/99 HIV-positive patients (6%) 
compared with 2/30 HIV-negative patients 
(7%). Two of the HIV-positive patients died 
while receiving radiation therapy.
Surgical management is set out in Table 3. 
The resection rate among HIV-posi-
tive patients was 13%, compared with 9% 
among HIV-negative patients. There was 
no difference in terms of up-front v. salvage 
resection. Two HIV-positive patients and 
no HIV-negative patients had R-1 resection. 
Seven HIV-positive patients (7%) and 2 
HIV-negative patients (7%) developed 
recurrence. The median disease-free interval 
was 14 months for HIV-positive patients 
compared with 10 months for those who 
were HIV-negative.
Complications of chemotherapy and 
radio therapy occurred with similar frequency 
in the two groups (Table 4). The frequency of 
afebrile neutropenia was slightly higher in 
HIV-positive than in HIV-negative patients, 
and anaemia was only seen in HIV-positive 
patients.
The median follow-up for the HIV-
positive patients was 9 (IQR 3 - 21) months 
and that for the HIV-negative patients 11.5 
(IQR 5 - 24.5) months. Fig. 4 shows the 
Kaplan-Meier survival curves. Overall, 
the 5-year survival rate for HIV-positive 
and negative patients was 57% and 63%, 
respectively (p=0.0240). Median survival 
was 23.1 months for HIV-negative patients 
and 29.8 months for HIV-positive patients 
(not statistically significant).
Discussion
This study presents an audit of anal 
squamous cell carcinoma and analyses 
differences in the demographic profile, 
clinicopathological features, treatment 
tolerance and final outcome between HIV-
positive and HIV-negative patients with 
squamous cell carcinoma of the anus in 
our unit. In evaluating the influence of HIV 
infection on presentation of these patients 
and outcome of treatment, we have made a 
number of observations.
The median duration of symptoms in HIV-
negative and positive patients was similar. 
Reasons for delay in treatment included 
late presentation by the patient in seeking 
medical attention, incorrect diagnosis by the 
primary doctor, and delayed referral by the 
referring doctor.
According to the 2014 SA registry, anal 
cancer comprised 0.33% of cancers in 
females v. 0.26% in males, with 125 new cases 
annually in females v. 95 in males. [16] The 
present study demonstrated an increasing 
accrual of patients with squamous cell anal 
carcinoma over the years. The rising rate 
of anal cancer can partly be explained by 
the longer life expectancy of HIV-infected 
patients on ART and an increased incidence 
of HPV infections,[15,17] in addition to possible 
Total anal carcinomas,
N=323
Non-SCC, N=48
• Adenocarcinoma, n=45
• Adenosquamous, n=1
• Melanoma, n=1
• Neuroendocrine tumour, n=1
Total SCCs.
n=275
Carcinoma in situ,
n=7
SCCs available 
for analysis,
n=268
HIV status unknown,
n=100
HIV-positive,
n=135
HIV-negative,
n=33
Fig. 1. Flow diagram illustrating the study inclusion and exclusion criteria and describing the patients 
with anal squamous cell carcinoma eligible for initial analysis. (SCC = squamous cell carcinoma.)
Table 1. Profile of 168 patients with anal squamous cell carcinoma stratified according to HIV status†
Characteristics Total (N=268) HIV-positive (n=135) HIV-negative (n=33)
Age (years), median (IQR) 44 (37 - 57) 40 (34 - 45)* 52 (48 - 58)*
Male, n 84 37 12
Female, n 184 98 21
Male/female ratio 1:2.2 1:2.7 1:1.8
CD4+ count (cells/µL), median n/a 355 n/a
Antiretroviral therapy n/a 50 n/a
Margin, n 183 90 17
Canal, n 85 45 16
Margin/canal distribution ratio 2.2:1 2:1 1:1
IQR = interquartile range; n/a = not applicable.
*p<0.0001 (χ2 test).
†Patients whose HIV status was unknown were not included.
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increasing awareness of the disease on the 
part of patients and doctors and availability 
of the oncology services at IALCH.
Anal cancer traditionally affects older 
women more than men, but the incidence is 
increasing in younger women, homosexual 
men and patients with HIV infection.[7] This 
is not surprising, because HPV infection 
in immunocompromised patients tends 
to act synergistically with HIV and leads 
to eventual carcinogenesis.[8] The female 
predominance that was observed in both 
groups in this study is in keeping with 
the SA and international literature, which 
also reports a female preponderance.[4,9,14,17] 
Notably, however, the relative preponderance 
of female patients was more pronounced 
in the HIV-positive group. This relative 
predominance is not surprising, since 
various surveys show that women continue 
to account for a disproportionate percentage 
of new HIV infections among adults in sub-
Saharan Africa, where they comprise 59% of 
the affected population.[18,19] One reason for 
this difference is that men are less likely than 
women to use health services and are less 
likely to take an HIV test.[19]
The mean age of presentation for the 
whole group of 48 years was approximately 
a decade younger than the 56 years reported 
in the international literature. [11,12,14] In 
addition, HIV-positive patients presented 
over a decade earlier than their HIV-
negative counterparts. The younger age 
of presentation in HIV-positive patients 
confirms our hypothesis that patients with 
anal squamous cell carcinoma and HIV 
co-infection present at an earlier age than 
those without HIV infection. This tendency 
for HIV-positive patients to present 
at a younger age has been observed by 
others. [7,11,13,17]
Anal margin cancers were twice as 
common as anal canal cancers in our study 
Table 2. Primary management of patients with anal squamous cell carcinoma
Management HIV-positive (N=135), n (%)/n HIV-negative (N=33), n (%)/n
Definitive therapy 69 (51.1) 17 (51.5)
Chemoradiation 58 17
Chemotherapy 4 0
Radiotherapy 7 0
Palliative therapy 32 (23.7) 12 (36.4)
Radiotherapy 20 7
Chemotherapy + radiation 12 3
Chemotherapy 0 2
No treatment 34 (24.4) 4 (12.1)
Did not arrive 15 1
Planned for treatment – did not return 10 2
Poor general condition 5 0
Complete surgical resection 3 1
Previous radiotherapy 1 0
Table 3. Surgical resection in patients with anal squamous cell carcinoma
Surgical management HIV-positive (N=135), n (%)/n HIV-negative (N=33), n (%)/n
Resection 17 (12.6) 3 (9.0)
Up-front resection 8 (5.9) 1 (3.0)
Salvage resection 9 (6.7) 2 (6.1)
Refused resection 1 1
Trial of dissection 1 0
Type of surgery
WLE 11 2
A-P resection 6 1
WLE = wide local excision; A-P = abdominoperineal.
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Fig. 2. Annual accrual of patients with SCC (p=0.680). (SCC = squamous cell carcinoma.)
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group as a whole. On subanalysis according to HIV status, anal 
margin cancers were twice as common as anal canal cancers in HIV-
positive patients, whereas the disease occurred with similar frequency 
in the anal canal and the anal margin in HIV-negative patients. It 
therefore appears that the HIV-positive patients added considerably 
to the number of cancers in the anal margin, which led to the whole 
group demonstrating an anal margin preponderance. This finding 
of anal margin preponderance is in contrast to other studies on anal 
cancer, which show a preponderance of anal canal cancers.[15] Another 
local study on anal cancer similarly observed a preponderance of anal 
margin lesions.[20] A limitation of previous international studies on 
anal cancer is their tendency to consider anal cancer as a homogeneous 
entity or to describe one or another of the disease sites.[11,20]
It was interesting to observe that HIV-negative patients presented 
with a higher proportion of stage IV disease than HIV-positive 
patients (16% v. 9%) (Fig. 3). These HIV-negative patients were of 
older age and mostly presented with lung metastases. We believe that 
this observation cannot be generalised to all patients with squamous 
cell anal carcinoma, as the numbers in our series were small.
The majority of both HIV-positive and HIV-negative patients 
presented with locally advanced stage disease owing to late 
presentation, which resulted in only 13% and 9%, respectively, 
meeting the criteria for resection. The fact that only about half of the 
patients in both groups were eligible for definitive chemoradiation 
can also be attributed to presentation with locally advanced disease, 
since only a small proportion had metastatic disease. Inasmuch as 
immunocompromised patients are thought to have more biologically 
aggressive tumours, independent of the lesion’s actual histological 
grade,[10] it is counter-intuitive that proportions of patients who 
were not eligible for definitive therapy were similar in the two 
groups. However, the small number of HIV-negative patients makes 
comparison difficult.
Evidence seems to suggest that, in the modern era of ART, 
anal cancer recurrence and survival outcomes are similar in HIV-
infected and HIV-uninfected patients, but HIV-infected patients 
may experience more toxicity[15] because of altered sensitivity to 
radiotherapy.[21] However, the present study showed tolerance to 
chemotherapy and radiotherapy to be similar in the two groups. 
Anaemia was observed only in HIV-positive patients, but again the 
number of HIV-negative patients was too small to make a statistical 
comparison. Studies with larger numbers will assist in determining 
whether or not toxicity is increased in HIV-positive patients. Five-
year survival was significantly longer for HIV-negative patients 
than for those who were HIV-positive, supporting the view that 
HIV-positive patients with anal cancer tend to do badly in terms of 
survival. According to the SEER data, the 5-year survival rate in the 
USA is 68.2%.[2] An SA study by Robertson et al.,[22] describing only 
anal canal squamous cell carcinoma, reported a 5-year survival rate 
of 65.6%, which is slightly higher than the 57% and 63% for HIV-
positive and negative patients, respectively, in the present series.
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Table 4. Complications of treatment in 129 patients with anal squamous cell carcinoma receiving oncological therapy
Complications HIV-positive (N=99), n (%)/n HIV-negative (N=30), n (%)/n
Total with complications 33 (33.3) 10 (33.3)
Total with chemotherapy complications 20 (20.2)* 4 (13.3)
Afebrile neutropenia 10 (10.1) 2 (6.7)
Anaemia 7 0
Miscellaneous 4 2
Total with radiation complications 21 (21.2) 6 (20.0)
Skin reaction 16 6
Radiation proctitis 3 0
Radiation cystitis 1 0
Rectovaginal fistula 1 0
*One patient had both anaemia and afebrile neutropenia.
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Study limitations
This study has certain limitations. The number of HIV-negative 
patients was very small. We were not able to estimate the duration 
of HIV infection between seroconversion and the development 
of anal cancer, or the duration of immune reconstitution after 
commencement of antiretroviral treatment. Knowledge of these 
two variables could contribute to understanding of the role of 
HIV infection and its treatment on carcinogenesis. We also did 
not evaluate individual patients’ sexual practices owing to the 
conservative cultural traditions in this community. Despite these 
limitations, the study accrued large enough numbers to reach 
important conclusions.
Conclusions
Although anal squamous cell carcinoma is a rare malignancy, 
in this series the prevalence was higher in HIV-positive patients 
than in those who were HIV-negative. HIV-positive patients were 
younger than their HIV-negative counterparts. The side-effects of 
chemoradiation occurred with similar frequency in the two groups, 
although anaemia was seen only in HIV-positive patients. Median 
survival of HIV-positive patients was lower. We recommend that 
patients with precursor lesions such as AIN and HIV co-infection 
should be offered closer surveillance, enabling earlier detection and 
appropriate treatment of invasive lesions. We are in agreement with 
others that condylomas should not be cauterised, but should always 
be resected and sent for histological evaluation.[20] Since HPV is a 
risk factor and a causative factor in 90% of anal cancers,[15] we agree 
with other authors that HPV vaccination should be considered as an 
intervention for the prevention of anal cancer.[9,23,24]
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